entrectinib
Selected indexed studies
- Entrectinib. (, 2012) [PMID:34633782]
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. (Lancet Oncol, 2020) [PMID:31838007]
- Entrectinib. (, 2006) [PMID:40127371]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Entrectinib. (2012) pubmed
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. (2020) pubmed
- Entrectinib. (2006) pubmed
- Entrectinib: First Global Approval. (2019) pubmed
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (2020) pubmed
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. (2022) pubmed
- Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. (2020) pubmed
- Entrectinib, a new multi-target inhibitor for cancer therapy. (2022) pubmed
- PMID:40857385 (2020) pubmed
- Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC. (2021) pubmed